Cripe Timothy P, Thomson Blythe, Boat Thomas F, Williams David A
Division of Hematology/Oncology, MLC R7015, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Acad Med. 2005 Nov;80(11):1012-8. doi: 10.1097/00001888-200511000-00008.
The translation of hypothesis-driven research laboratory findings about basic disease mechanisms into clinically useful tests or therapies, particularly in pediatric diseases, is time-consuming, expensive, and not well supported by traditional research grant mechanisms. Accordingly, the development of new drugs and clinical assays has typically been largely the domain of the pharmaceutical industry. Aside from partnering with for-profit companies, academic health centers are challenged to find ways to actively engage in biomedical research to bridge the gap between basic and clinical research. The Translational Research Initiative (TRI) at Cincinnati Children's Hospital Medical Center was launched in 2001 with the mission to build an institutional infrastructure for promoting and facilitating the clinical implementation of investigator-initiated basic research. The TRI's goals are to provide grant support for proposals that are translational in nature and that address serious diagnostic or therapeutic deficiencies in pediatric illnesses; to create and support specialized research cores and a specialized office that provides support for research protocol development and regulatory affairs; and to organize educational opportunities focused on bridging communication between basic and clinical scientists and encouraging multidisciplinary interactions. The authors describe the program structure and provide an interim outcome report as measured by extramural funding obtained, Investigational New Drug applications filed, manuscripts published, clinical trials launched, and educational initiatives created. The broad success of this program suggests that it might serve as a model for other academic health centers in promoting and conducting translational research.
将关于基本疾病机制的假设驱动型研究实验室成果转化为临床可用的检测方法或治疗手段，尤其是在儿科疾病方面，既耗时又昂贵，而且传统研究资助机制对此支持不足。因此，新药和临床检测方法的开发通常主要是制药行业的领域。除了与营利性公司合作外，学术健康中心还面临着寻找积极参与生物医学研究的方法，以弥合基础研究与临床研究之间差距的挑战。辛辛那提儿童医院医疗中心的转化研究倡议（TRI）于2001年启动，其使命是建立一个机构基础设施，以促进和推动研究者发起的基础研究的临床应用。TRI的目标是为具有转化性质且解决儿科疾病严重诊断或治疗缺陷的提案提供资助支持；创建并支持专门的研究核心以及一个为研究方案制定和监管事务提供支持的专门办公室；组织教育机会，重点是弥合基础科学家和临床科学家之间的沟通差距，并鼓励多学科互动。作者描述了该项目的结构，并提供了一份中期成果报告，报告内容包括获得的外部资金、提交的研究性新药申请、发表的手稿、开展的临床试验以及创建的教育倡议。该项目的广泛成功表明，它可能为其他学术健康中心促进和开展转化研究提供一个典范。
